checkAd

     229  0 Kommentare Endexx Contributes to Diabetic Neuropathy Case Study - Seite 2

    About Endexx

    Endexx provides innovative medical marijuana management and technology solutions. The company has two technology products that launched in 2014 -- the M3hub and the Autospense. Both products provide essential solutions to promote regulatory compliance and full accountability through "seed to sale" inventory management and tracking. Based on principles developed by the pharmacological industry, the m3hub database is the first standardized software platform for tracking pharmaceutical grade marijuana to support a Centralized Medical Marijuana Industry Repository and maintain compliance with the laws of State government and local regulatory bodies, as well as, provide a smooth transition to the eventual Federal mandates. The AutospenseTM is a high-tech marijuana inventory control and dispensing machine, which provides up to the minute accounting details and protects the security of the product as well as the patient. By automating the dispensing process, Autospense™ increases productivity and reduces costs for marijuana retailers, while enhancing their service quality by reducing transaction time for customers. Additionally, Endexx with its collaboration partners and consultants are developing two consumable product lines derived from industrial hemp that is organic and naturally rich in phytocannabinoids. Websites are: www.endexx.com, www.m3hub.com, www.autospense.com

    Safe Harbor Notice

    This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company's business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company's periodic filings with the Security and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.

    For further investor and media information, contact:

    Endexx Corporation
    Todd Davis
    Chairman & CEO
    endexx@endexx.com
    480-595-6900

    and

    Irth Communications
    Robert Haag
    Managing Director
    edxc@irthcommunications.com
    866-976-4784

    Seite 2 von 2



    Verfasst von Marketwired
    Endexx Contributes to Diabetic Neuropathy Case Study - Seite 2 CAVE CREEK, AZ--(Marketwired - Dec 9, 2014) - Endexx Corporation (OTC PINK: EDXC) announced today that it is providing its CBD (Cannabidiol) starter kit (M3Vape) to a voluntary patient study utilizing industrial hemp oil that is rich in CBD/CBDa, …

    Schreibe Deinen Kommentar

    Disclaimer